Metastatic Breast Cancer | Improving Outcomes with First-Line Endocrine-Based Therapy for Patients with HR-Positive, HER2-Negative Metastatic Breast Cancer

Featuring perspectives from Prof Francois-Clement Bidard and Dr Kevin Kalinsky, including the following topics:

Introduction: Confronting Metastatic Breast Cancer (mBC) (0:00)

Mechanisms of Resistance to Endocrine Therapy in HR-Positive mBC; Use of Oral Selective Estrogen Receptor Degraders (SERDs) — Dr Kalinsky (13:18)

Ongoing Evaluation of Early Therapeutic Switching for HR-Positive mBC Harboring ESR1 Mutations — Prof Bidard (35:52)

CME information and select publications

The skinny

The skinny isn't ready yet — notes appear once the transcript is processed.